rs149772375
Variant names:
Your query was ambiguous. Multiple possible variants found:
Variant summary
Our verdict is Benign. The variant received -16 ACMG points: 0P and 16B. BP4_StrongBP6_Very_StrongBS2
The NM_003184.4(TAF2):c.1655A>T(p.Tyr552Phe) variant causes a missense change. The variant allele was found at a frequency of 0.00243 in 1,613,806 control chromosomes in the GnomAD database, including 15 homozygotes. In-silico tool predicts a benign outcome for this variant. 14/22 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Likely benign (★★).
Frequency
Genomes: 𝑓 0.0019 ( 1 hom., cov: 31)
Exomes 𝑓: 0.0025 ( 14 hom. )
Consequence
TAF2
NM_003184.4 missense
NM_003184.4 missense
Scores
2
1
15
Clinical Significance
Conservation
PhyloP100: 6.27
Publications
5 publications found
Genes affected
TAF2 (HGNC:11536): (TATA-box binding protein associated factor 2) Initiation of transcription by RNA polymerase II requires the activities of more than 70 polypeptides. The protein that coordinates these activities is transcription factor IID (TFIID), which binds to the core promoter to position the polymerase properly, serves as the scaffold for assembly of the remainder of the transcription complex, and acts as a channel for regulatory signals. TFIID is composed of the TATA-binding protein (TBP) and a group of evolutionarily conserved proteins known as TBP-associated factors or TAFs. TAFs may participate in basal transcription, serve as coactivators, function in promoter recognition or modify general transcription factors (GTFs) to facilitate complex assembly and transcription initiation. This gene encodes one of the larger subunits of TFIID that is stably associated with the TFIID complex. It contributes to interactions at and downstream of the transcription initiation site, interactions that help determine transcription complex response to activators. [provided by RefSeq, Jul 2008]
TAF2 Gene-Disease associations (from GenCC):
- microcephaly-thin corpus callosum-intellectual disability syndromeInheritance: AR Classification: STRONG, MODERATE, SUPPORTIVE, LIMITED Submitted by: G2P, Orphanet, Labcorp Genetics (formerly Invitae), Ambry Genetics
Genome browser will be placed here
ACMG classification
Classification was made for transcript
Our verdict: Benign. The variant received -16 ACMG points.
BP4
Computational evidence support a benign effect (MetaRNN=0.008978754).
BP6
Variant 8-119788818-T-A is Benign according to our data. Variant chr8-119788818-T-A is described in ClinVar as Likely_benign. ClinVar VariationId is 436940.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars.
BS2
High Homozygotes in GnomAdExome4 at 14 AR gene
Transcripts
RefSeq
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | MANE | Protein | UniProt |
|---|---|---|---|---|---|---|---|---|
| TAF2 | NM_003184.4 | c.1655A>T | p.Tyr552Phe | missense_variant | Exon 13 of 26 | ENST00000378164.7 | NP_003175.2 |
Ensembl
| Gene | Transcript | HGVSc | HGVSp | Effect | Exon rank | TSL | MANE | Protein | Appris | UniProt |
|---|---|---|---|---|---|---|---|---|---|---|
| TAF2 | ENST00000378164.7 | c.1655A>T | p.Tyr552Phe | missense_variant | Exon 13 of 26 | 1 | NM_003184.4 | ENSP00000367406.2 | ||
| TAF2 | ENST00000686879.1 | c.1655A>T | p.Tyr552Phe | missense_variant | Exon 13 of 27 | ENSP00000509206.1 | ||||
| TAF2 | ENST00000685235.1 | c.1655A>T | p.Tyr552Phe | missense_variant | Exon 13 of 26 | ENSP00000510174.1 | ||||
| TAF2 | ENST00000688645.1 | c.1655A>T | p.Tyr552Phe | missense_variant | Exon 13 of 25 | ENSP00000509978.1 | ||||
| TAF2 | ENST00000523904.2 | c.1541A>T | p.Tyr514Phe | missense_variant | Exon 12 of 25 | 3 | ENSP00000430832.2 | |||
| TAF2 | ENST00000690144.1 | c.1655A>T | p.Tyr552Phe | missense_variant | Exon 13 of 26 | ENSP00000510548.1 | ||||
| TAF2 | ENST00000685202.1 | n.1655A>T | non_coding_transcript_exon_variant | Exon 13 of 27 | ENSP00000509214.1 | |||||
| TAF2 | ENST00000685503.1 | n.*1047A>T | non_coding_transcript_exon_variant | Exon 13 of 26 | ENSP00000509198.1 | |||||
| TAF2 | ENST00000685663.1 | n.*1527A>T | non_coding_transcript_exon_variant | Exon 15 of 28 | ENSP00000508988.1 | |||||
| TAF2 | ENST00000685684.1 | n.*3122A>T | non_coding_transcript_exon_variant | Exon 12 of 25 | ENSP00000509441.1 | |||||
| TAF2 | ENST00000685824.1 | n.*1356A>T | non_coding_transcript_exon_variant | Exon 11 of 24 | ENSP00000510262.1 | |||||
| TAF2 | ENST00000685876.1 | n.*1373A>T | non_coding_transcript_exon_variant | Exon 14 of 27 | ENSP00000510493.1 | |||||
| TAF2 | ENST00000685993.1 | n.*1470A>T | non_coding_transcript_exon_variant | Exon 12 of 25 | ENSP00000510102.1 | |||||
| TAF2 | ENST00000686098.1 | n.*300A>T | non_coding_transcript_exon_variant | Exon 12 of 25 | ENSP00000509102.1 | |||||
| TAF2 | ENST00000688037.1 | n.*1074A>T | non_coding_transcript_exon_variant | Exon 10 of 23 | ENSP00000510169.1 | |||||
| TAF2 | ENST00000689164.1 | n.*300A>T | non_coding_transcript_exon_variant | Exon 11 of 24 | ENSP00000508729.1 | |||||
| TAF2 | ENST00000689919.1 | n.*1373A>T | non_coding_transcript_exon_variant | Exon 14 of 26 | ENSP00000510768.1 | |||||
| TAF2 | ENST00000690808.1 | n.*891A>T | non_coding_transcript_exon_variant | Exon 13 of 26 | ENSP00000509791.1 | |||||
| TAF2 | ENST00000690922.1 | n.*67A>T | non_coding_transcript_exon_variant | Exon 13 of 26 | ENSP00000509498.1 | |||||
| TAF2 | ENST00000691847.1 | n.*956A>T | non_coding_transcript_exon_variant | Exon 12 of 24 | ENSP00000509663.1 | |||||
| TAF2 | ENST00000691880.1 | n.*1311A>T | non_coding_transcript_exon_variant | Exon 12 of 25 | ENSP00000508515.1 | |||||
| TAF2 | ENST00000692518.1 | n.*1356A>T | non_coding_transcript_exon_variant | Exon 11 of 25 | ENSP00000508959.1 | |||||
| TAF2 | ENST00000692707.1 | n.*1523A>T | non_coding_transcript_exon_variant | Exon 15 of 28 | ENSP00000509024.1 | |||||
| TAF2 | ENST00000692916.1 | n.*1042A>T | non_coding_transcript_exon_variant | Exon 12 of 25 | ENSP00000509603.1 | |||||
| TAF2 | ENST00000685503.1 | n.*1047A>T | 3_prime_UTR_variant | Exon 13 of 26 | ENSP00000509198.1 | |||||
| TAF2 | ENST00000685663.1 | n.*1527A>T | 3_prime_UTR_variant | Exon 15 of 28 | ENSP00000508988.1 | |||||
| TAF2 | ENST00000685684.1 | n.*3122A>T | 3_prime_UTR_variant | Exon 12 of 25 | ENSP00000509441.1 | |||||
| TAF2 | ENST00000685824.1 | n.*1356A>T | 3_prime_UTR_variant | Exon 11 of 24 | ENSP00000510262.1 | |||||
| TAF2 | ENST00000685876.1 | n.*1373A>T | 3_prime_UTR_variant | Exon 14 of 27 | ENSP00000510493.1 | |||||
| TAF2 | ENST00000685993.1 | n.*1470A>T | 3_prime_UTR_variant | Exon 12 of 25 | ENSP00000510102.1 | |||||
| TAF2 | ENST00000686098.1 | n.*300A>T | 3_prime_UTR_variant | Exon 12 of 25 | ENSP00000509102.1 | |||||
| TAF2 | ENST00000688037.1 | n.*1074A>T | 3_prime_UTR_variant | Exon 10 of 23 | ENSP00000510169.1 | |||||
| TAF2 | ENST00000689164.1 | n.*300A>T | 3_prime_UTR_variant | Exon 11 of 24 | ENSP00000508729.1 | |||||
| TAF2 | ENST00000689919.1 | n.*1373A>T | 3_prime_UTR_variant | Exon 14 of 26 | ENSP00000510768.1 | |||||
| TAF2 | ENST00000690808.1 | n.*891A>T | 3_prime_UTR_variant | Exon 13 of 26 | ENSP00000509791.1 | |||||
| TAF2 | ENST00000690922.1 | n.*67A>T | 3_prime_UTR_variant | Exon 13 of 26 | ENSP00000509498.1 | |||||
| TAF2 | ENST00000691847.1 | n.*956A>T | 3_prime_UTR_variant | Exon 12 of 24 | ENSP00000509663.1 | |||||
| TAF2 | ENST00000691880.1 | n.*1311A>T | 3_prime_UTR_variant | Exon 12 of 25 | ENSP00000508515.1 | |||||
| TAF2 | ENST00000692518.1 | n.*1356A>T | 3_prime_UTR_variant | Exon 11 of 25 | ENSP00000508959.1 | |||||
| TAF2 | ENST00000692707.1 | n.*1523A>T | 3_prime_UTR_variant | Exon 15 of 28 | ENSP00000509024.1 | |||||
| TAF2 | ENST00000692916.1 | n.*1042A>T | 3_prime_UTR_variant | Exon 12 of 25 | ENSP00000509603.1 |
Frequencies
GnomAD3 genomes AF: 0.00188 AC: 286AN: 152150Hom.: 1 Cov.: 31 show subpopulations
GnomAD3 genomes
AF:
AC:
286
AN:
152150
Hom.:
Cov.:
31
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD2 exomes AF: 0.00266 AC: 669AN: 251358 AF XY: 0.00260 show subpopulations
GnomAD2 exomes
AF:
AC:
669
AN:
251358
AF XY:
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.00249 AC: 3634AN: 1461538Hom.: 14 Cov.: 30 AF XY: 0.00251 AC XY: 1828AN XY: 727096 show subpopulations
GnomAD4 exome
AF:
AC:
3634
AN:
1461538
Hom.:
Cov.:
30
AF XY:
AC XY:
1828
AN XY:
727096
show subpopulations
African (AFR)
AF:
AC:
11
AN:
33474
American (AMR)
AF:
AC:
269
AN:
44724
Ashkenazi Jewish (ASJ)
AF:
AC:
194
AN:
26128
East Asian (EAS)
AF:
AC:
0
AN:
39656
South Asian (SAS)
AF:
AC:
84
AN:
86252
European-Finnish (FIN)
AF:
AC:
37
AN:
53416
Middle Eastern (MID)
AF:
AC:
37
AN:
5762
European-Non Finnish (NFE)
AF:
AC:
2783
AN:
1111742
Other (OTH)
AF:
AC:
219
AN:
60384
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.450
Heterozygous variant carriers
0
179
357
536
714
893
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Exome Het
Exome Hom
Variant carriers
0
102
204
306
408
510
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
GnomAD4 genome AF: 0.00187 AC: 285AN: 152268Hom.: 1 Cov.: 31 AF XY: 0.00167 AC XY: 124AN XY: 74458 show subpopulations
GnomAD4 genome
AF:
AC:
285
AN:
152268
Hom.:
Cov.:
31
AF XY:
AC XY:
124
AN XY:
74458
show subpopulations
African (AFR)
AF:
AC:
14
AN:
41580
American (AMR)
AF:
AC:
49
AN:
15278
Ashkenazi Jewish (ASJ)
AF:
AC:
17
AN:
3468
East Asian (EAS)
AF:
AC:
1
AN:
5160
South Asian (SAS)
AF:
AC:
6
AN:
4830
European-Finnish (FIN)
AF:
AC:
3
AN:
10622
Middle Eastern (MID)
AF:
AC:
0
AN:
294
European-Non Finnish (NFE)
AF:
AC:
172
AN:
68018
Other (OTH)
AF:
AC:
6
AN:
2106
Allele Balance Distribution
Red line indicates average allele balance
Average allele balance: 0.469
Heterozygous variant carriers
0
12
24
36
48
60
0.00
0.20
0.40
0.60
0.80
0.95
Allele balance
Age Distribution
Genome Het
Genome Hom
Variant carriers
0
4
8
12
16
20
<30
30-35
35-40
40-45
45-50
50-55
55-60
60-65
65-70
70-75
75-80
>80
Age
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
8
ALSPAC
AF:
AC:
4
ESP6500AA
AF:
AC:
0
ESP6500EA
AF:
AC:
26
ExAC
AF:
AC:
314
Asia WGS
AF:
AC:
2
AN:
3476
ClinVar
Significance: Likely benign
Submissions summary: Benign:5
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not provided Benign:3
Sep 01, 2025
CeGaT Center for Human Genetics Tuebingen
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
TAF2: BS2
Breakthrough Genomics, Breakthrough Genomics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:not provided
Jan 20, 2025
Labcorp Genetics (formerly Invitae), Labcorp
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
not specified Benign:1
Aug 13, 2018
Genetic Services Laboratory, University of Chicago
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
Microcephaly-thin corpus callosum-intellectual disability syndrome Benign:1
Feb 10, 2022
Fulgent Genetics, Fulgent Genetics
Significance:Likely benign
Review Status:criteria provided, single submitter
Collection Method:clinical testing
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Benign
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
DANN
Benign
DEOGEN2
Benign
T
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Pathogenic
D
LIST_S2
Uncertain
D
M_CAP
Benign
T
MetaRNN
Benign
T
MetaSVM
Benign
T
MutationAssessor
Benign
N
PhyloP100
PrimateAI
Pathogenic
D
PROVEAN
Benign
N
REVEL
Benign
Sift
Benign
T
Sift4G
Benign
T
Vest4
ClinPred
T
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at
Publications
You must be logged in to view publications. This limit was set because tens of millions (!) of queries from AI bots are generated daily.